000270302 001__ 270302
000270302 005__ 20240808164318.0
000270302 0247_ $$2doi$$a10.1016/S2215-0366(24)00136-6
000270302 0247_ $$2ISSN$$a2215-0366
000270302 0247_ $$2ISSN$$a2215-0374
000270302 0247_ $$2altmetric$$aaltmetric:164549356
000270302 0247_ $$2pmid$$apmid:38879276
000270302 037__ $$aDZNE-2024-00774
000270302 082__ $$a610
000270302 1001_ $$aSalahuddin, Nurul Husna$$b0
000270302 245__ $$aPsychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis
000270302 260__ $$aPhiladelphia, Pa.$$bElsevier$$c2024
000270302 3367_ $$2DRIVER$$aarticle
000270302 3367_ $$2DataCite$$aOutput Types/Journal article
000270302 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1719823090_19443
000270302 3367_ $$2BibTeX$$aARTICLE
000270302 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000270302 3367_ $$00$$2EndNote$$aJournal Article
000270302 520__ $$a Many patients with schizophrenia have symptoms that do not respond to antipsychotics. This condition is called treatment-resistant schizophrenia and has not received specific attention as opposed to general schizophrenia. Psychological and psychosocial interventions as an add-on treatment to pharmacotherapy could be useful, but their role and comparative efficacy to each other and to standard care in this population are not known. We investigated the efficacy, acceptability, and tolerability of psychological and psychosocial interventions for patients with treatment-resistant schizophrenia.In this systematic review and network meta-analysis (NMA), we searched for published and unpublished randomised controlled trials (RCTs) through a systematic database search in BIOSIS, CINAHL, Embase, LILACS, MEDLINE, PsychInfo, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform for articles published from inception up to Jan 31, 2020. We also searched the Cochrane Schizophrenia Group registry for studies published from inception up to March 31, 2022, and PubMed and Cochrane CENTRAL for studies published from inception up to July 31, 2023. We included RCTs that included patients with treatment-resistant schizophrenia. The primary outcome was overall symptoms. We did random-effects pairwise meta-analyses and NMAs to calculate standardised mean differences (SMDs) or risk ratios with 95% CIs. No people with lived experience were involved throughout the research process. The study protocol was registered in PROSPERO, CRD42022358696.We identified 30 326 records, excluding 24 526 by title and abstract screening. 5762 full-text articles were assessed for eligibility, of which 5540 were excluded for not meeting the eligibility criteria, and 222 reports corresponding to 60 studies were included in the qualitative synthesis. Of these, 52 RCTs with 5034 participants (1654 [33·2%] females and 3325 [66·8%] males with sex indicated) comparing 20 psychological and psychosocial interventions provided data for the NMA. Mean age of participants was 38·05 years (range 23·10-48·50). We aimed to collect ethnicity data, but they were scarcely reported. According to the quality of evidence, cognitive behavioural therapy for psychosis (CBTp; SMD -0·22, 95% CI -0·35 to -0·09, 35 trials), virtual reality intervention (SMD -0·41, -0·79 to -0·02, four trials), integrated intervention (SMD -0·70, -1·18 to -0·22, three trials), and music therapy (SMD -1·27, -1·83 to -0·70, one study) were more efficacious than standard care in reducing overall symptoms. No indication of publication bias was identified.We provide robust findings that CBTp can reduce the overall symptoms of patients with treatment-resistant schizophrenia, and therefore clinicians can prioritise this intervention in their clinical practice. Other psychological and psychosocial interventions showed promising results but need further investigation.DAAD-ASFE.
000270302 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000270302 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000270302 650_2 $$2MeSH$$aHumans
000270302 650_2 $$2MeSH$$aNetwork Meta-Analysis
000270302 650_2 $$2MeSH$$aPsychosocial Intervention: methods
000270302 650_2 $$2MeSH$$aSchizophrenia, Treatment-Resistant: therapy
000270302 650_2 $$2MeSH$$aRandomized Controlled Trials as Topic
000270302 650_2 $$2MeSH$$aPsychotherapy: methods
000270302 650_2 $$2MeSH$$aAntipsychotic Agents: therapeutic use
000270302 650_2 $$2MeSH$$aTreatment Outcome
000270302 650_2 $$2MeSH$$aSchizophrenia: therapy
000270302 650_7 $$2NLM Chemicals$$aAntipsychotic Agents
000270302 7001_ $$aSchütz, Alexandra$$b1
000270302 7001_ $$aPitschel-Walz, Gabi$$b2
000270302 7001_ $$aMayer, Susanna Franziska$$b3
000270302 7001_ $$aChaimani, Anna$$b4
000270302 7001_ $$aSiafis, Spyridon$$b5
000270302 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b6$$udzne
000270302 7001_ $$aLeucht, Stefan$$b7
000270302 7001_ $$aBighelli, Irene$$b8
000270302 773__ $$0PERI:(DE-600)2771442-1$$a10.1016/S2215-0366(24)00136-6$$gVol. 11, no. 7, p. 545 - 553$$n7$$p545 - 553$$tThe lancet / Psychiatry$$v11$$x2215-0366$$y2024
000270302 8564_ $$uhttps://pub.dzne.de/record/270302/files/DZNE-2024-00774%20SUP.pdf
000270302 8564_ $$uhttps://pub.dzne.de/record/270302/files/DZNE-2024-00774.pdf$$yOpenAccess
000270302 8564_ $$uhttps://pub.dzne.de/record/270302/files/DZNE-2024-00774%20SUP.pdf?subformat=pdfa$$xpdfa
000270302 8564_ $$uhttps://pub.dzne.de/record/270302/files/DZNE-2024-00774.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000270302 909CO $$ooai:pub.dzne.de:270302$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000270302 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000270302 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000270302 9141_ $$y2024
000270302 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-24
000270302 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000270302 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET PSYCHIAT : 2022$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000270302 915__ $$0StatID:(DE-HGF)9960$$2StatID$$aIF >= 60$$bLANCET PSYCHIAT : 2022$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000270302 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000270302 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x0
000270302 980__ $$ajournal
000270302 980__ $$aVDB
000270302 980__ $$aUNRESTRICTED
000270302 980__ $$aI:(DE-2719)5000007
000270302 9801_ $$aFullTexts